CYP39A1 and neoplasm: The mean survival for CYP39A1 negative/weak staining tumours (n=617) was 117 months (95% CI 109-126), declining to 33 months (95% CI 17-50) for patients whose tumours demonstrated moderate immunostaining for CYP39A1 (n=12).